Atezolizumab
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Carcinoma, Non-Small-Cell Lung
Conditions
Carcinoma, Non-Small-Cell Lung
Trial Timeline
Oct 25, 2017 → Apr 7, 2022
NCT ID
NCT03285763About Atezolizumab
Atezolizumab is a approved stage product being developed by Roche for Carcinoma, Non-Small-Cell Lung. The current trial status is completed. This product is registered under clinical trial identifier NCT03285763. Target conditions include Carcinoma, Non-Small-Cell Lung.
What happened to similar drugs?
20 of 20 similar drugs in Carcinoma, Non-Small-Cell Lung were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07284121 | Pre-clinical | Recruiting |
| NCT05770102 | Phase 2/3 | Recruiting |
| NCT05300282 | Phase 1/2 | Recruiting |
| NCT05047250 | Phase 3 | Active |
| NCT05038657 | Phase 2 | UNKNOWN |
| NCT05171777 | Phase 2 | Completed |
| NCT05470595 | Phase 2 | Active |
| NCT04624399 | Phase 2 | Recruiting |
| NCT04660344 | Phase 3 | Active |
| NCT04321330 | Phase 2 | Completed |
| NCT04462276 | Phase 2 | Completed |
| NCT04273061 | Phase 2 | Recruiting |
| NCT03548428 | Phase 2 | Recruiting |
| NCT04221529 | Phase 2 | Completed |
| NCT03922997 | Phase 3 | Completed |
| NCT03976518 | Phase 2 | Completed |
| NCT03782207 | Pre-clinical | Active |
| NCT03697850 | Phase 2 | Active |
| NCT03357224 | Phase 2 | Terminated |
| NCT03559647 | Pre-clinical | Completed |
Competing Products
20 competing products in Carcinoma, Non-Small-Cell Lung